Phase I study of oral nintedanib combined with docetaxel in previously treated Japanese patients with advanced non-small cell lung cancer (NSCLC)

被引：0
|
作者：
Okamoto, I. [1 ,2 ,3 ]
Miyazaki, M. [4 ]
Takeda, M. [4 ]
Azuma, K. [4 ]
Hayashi, H. [4 ]
Seto, T. [5 ]
Konishi, K. [6 ]
Sarashina, A. [7 ]
Kaiser, R. [8 ]
Nakagawa, K. [4 ]
机构：
[1] Kinki Univ Hosp, Fukuoka, Japan
[2] Kyushu Univ Hosp, Fukuoka 812, Japan
[3] Kyushu Univ Hosp, Ctr Clin & Translat Res, Fukuoka 812, Japan
[4] Kinki Univ, Sch Med, Osaka 589, Japan
[5] Kyushu Natl Canc Ctr, Fukuoka, Japan
[6] Nippon Boehringer Ingelheim Co Ltd, Oncol Clin Res, Shinagawa Tokyo, Japan
[7] Nippon Boehringer Ingelheim Co Ltd, Med Dev Div, Kobe, Hyogo, Japan
[8] Boehringer Ingelheim Pharma GmbH Co KG, Biberach, Germany
来源：
EUROPEAN JOURNAL OF CANCER | 2013年 / 49卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
3506
引用
收藏
页码：S830 / S831
页数：2
相关论文
共 50 条
  • [21] Bortezomib ± docetaxel in previously treated advanced non-small cell lung cancer: Interim analysis of a phase 2 study
    Fanucchi, Michael
    Belt, Robert
    Fossella, Frank
    Natale, Ronald
    Robert, Francisco
    Fidias, Panos
    Kelly, Karen
    Kashala, Oscar
    Schenkein, David
    Schiller, Joan
    ANNALS OF ONCOLOGY, 2004, 15 : 170 - 170
  • [22] Monotherapy with docetaxel in previously treated patients with advanced non-small cell lung carcinoma
    Courousis, C
    Androulakis, N
    Heras, P
    Vamvakas, I
    Metaxaris, G
    Souklakos, J
    Vlastos, F
    Dimadi, M
    Vossos, A
    Aravosita, P
    Georgopoulou, T
    Papandreou, A
    Hatzidaki, D
    Papadakis, E
    Georgoulias, V
    2ND INTERNATIONAL CONGRESS ON LUNG CANCER, 1996, : 571 - 574
  • [23] A phase II trial of denileukin diftitox in patients with previously treated advanced non-small cell lung cancer (NSCLC).
    Lewis, MAG
    JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (16) : 653S - 653S
  • [24] A phase I study of neoadjuvant cisplatin (C), docetaxel (D) and nintedanib (N) for resectable non-small cell lung cancer (NSCLC).
    Cascone, Tina
    Sepesi, Boris
    Lin, Heather Y.
    Kalhor, Neda
    Zhang, Jianjun
    Fossella, Frank V.
    Tsao, Anne S.
    Lam, Vincent K.
    Lu, Charles
    Mott, Frank
    Simon, George R.
    Antonoff, Mara
    Mehran, Reza J.
    Rice, David C.
    Vaporciyan, Ara A.
    Godoy, Myrna
    Lee, J. Jack
    Swisher, Stephen
    William, Nassib William
    Heymach, John
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [25] Phase II trial of capecitabine combined with docetaxel in previously treated patients with non-small cell lung cancer: A randomized controlled study
    Lin, Qiang
    Meng, Fan-Jie
    Liu, Yue'e
    Wang, Na
    Ren, Xiao-Cang
    Chen, Xue-Ji
    Ge, Xiao-Hui
    Liu, Chao-Xing
    Hui, Jing
    Wang, Dong-Ying
    Cao, Bin
    Zhao, Yannan
    ONCOLOGY LETTERS, 2012, 3 (04) : 761 - 766
  • [26] ERLOTINIB AND BEXAROTENE FOR PREVIOUSLY TREATED ADVANCED NON-SMALL CELL LUNG CANCER (NSCLC)
    Dragnev, K. H.
    Seltzer, M.
    Rigas, J. R.
    DiSalvo, W. M.
    Simeone, S.
    Johnstone, D.
    Nugent, W.
    Waxman, S.
    Dmitrovsky, E.
    ANNALS OF ONCOLOGY, 2008, 19 : 102 - 102
  • [27] Phase I/II study of docetaxel combined with resminostat, an oral hydroxamic acid HDAC inhibitor, for advanced non-small cell lung cancer in patients previously treated with platinum-based chemotherapy
    Tambo, Yuichi
    Hosomi, Yukio
    Sakai, Hiroshi
    Nogami, Naoyuki
    Atagi, Shinji
    Sasaki, Yasutsuna
    Kato, Terufumi
    Takahashi, Toshiaki
    Seto, Takashi
    Maemondo, Makoto
    Nokihara, Hiroshi
    Koyama, Ryo
    Nakagawa, Kazuhiko
    Kawaguchi, Tomoya
    Okamura, Yuta
    Nakamura, Osamu
    Nishio, Makoto
    Tamura, Tomohide
    INVESTIGATIONAL NEW DRUGS, 2017, 35 (02) : 217 - 226
  • [28] Phase I/II study of docetaxel combined with resminostat, an oral hydroxamic acid HDAC inhibitor, for advanced non-small cell lung cancer in patients previously treated with platinum-based chemotherapy
    Yuichi Tambo
    Yukio Hosomi
    Hiroshi Sakai
    Naoyuki Nogami
    Shinji Atagi
    Yasutsuna Sasaki
    Terufumi Kato
    Toshiaki Takahashi
    Takashi Seto
    Makoto Maemondo
    Hiroshi Nokihara
    Ryo Koyama
    Kazuhiko Nakagawa
    Tomoya Kawaguchi
    Yuta Okamura
    Osamu Nakamura
    Makoto Nishio
    Tomohide Tamura
    Investigational New Drugs, 2017, 35 : 217 - 226
  • [29] Phase II Study of Dasatinib in Previously Treated Patients with Advanced Non-Small Cell Lung Cancer
    Kelley, Michael J.
    Jha, Gautam
    Shoemaker, Debra
    Herndon, James E., II
    Gu, Lin
    Barry, William T.
    Crawford, Jeffrey
    Ready, Neal
    CANCER INVESTIGATION, 2017, 35 (01) : 32 - 35
  • [30] SAPPHIRE: Phase III study of sitravatinib plus nivolumab versus docetaxel in patients with previously treated advanced non-squamous non-small cell lung cancer (NSCLC)
    Borghaei, H.
    Johnson, M. L.
    Garon, E. B.
    He, K.
    Planchard, D.
    Reck, M.
    Popat, S.
    Herbst, R. S.
    Leal, T. A.
    Dumoulin, D.
    De Marinis, F.
    Reynolds, C. H.
    Theelen, W. S. M. E.
    Percent, I.
    Calderon, V. Gutierrez
    Flandin, A. C. Madroszyk
    Shazer, R. L.
    Yan, X.
    Harrigan, R.
    Peters, S.
    ANNALS OF ONCOLOGY, 2023, 34 : S1308 - S1308
12345